Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure

There is little evidence on the use of sodium−glucose cotransporter 2 inhibitors in hospitalised patients. This work aims to analyse the glycaemic and clinical efficacy and safety of empagliflozin continuation in patients with type 2 diabetes hospitalised for acute decompensated heart failure. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez-Belmonte, Luis M., Ricci, Michele, Sanz-Cánovas, Jaime, Millán-Gómez, Mercedes, Osuna-Sánchez, Julio, Ruiz-Moreno, M. Isabel, Bernal-López, M. Rosa, López-Carmona, María D., Jiménez-Navarro, Manuel, Gómez-Doblas, Juan J., Lara, José P., Gómez-Huelgas, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396978/
https://www.ncbi.nlm.nih.gov/pubmed/34441835
http://dx.doi.org/10.3390/jcm10163540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396978/
https://www.ncbi.nlm.nih.gov/pubmed/34441835
http://dx.doi.org/10.3390/jcm10163540

Ejemplares similares